Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Sampling and detection of airborne influenza virus towards point-of-care applications.

Ladhani L, Pardon G, Meeuws H, van Wesenbeeck L, Schmidt K, Stuyver L, van der Wijngaart W.

PLoS One. 2017 Mar 28;12(3):e0174314. doi: 10.1371/journal.pone.0174314. eCollection 2017.

2.

Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA.

Leirs K, Tewari Kumar P, Decrop D, Pérez-Ruiz E, Leblebici P, Van Kelst B, Compernolle G, Meeuws H, Van Wesenbeeck L, Lagatie O, Stuyver L, Gils A, Lammertyn J, Spasic D.

Anal Chem. 2016 Sep 6;88(17):8450-8. doi: 10.1021/acs.analchem.6b00502. Epub 2016 Aug 15.

PMID:
27487722
3.

A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.

Van Wesenbeeck L, D'Haese D, Tolboom J, Meeuws H, Dwyer DE, Holmes M, Ison MG, Katz K, McGeer A, Sadoff J, Weverling GJ, Stuyver L.

Open Forum Infect Dis. 2015 Nov 3;2(4):ofv166. doi: 10.1093/ofid/ofv166. eCollection 2015 Dec.

4.

Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring.

Van Wesenbeeck L, Meeuws H, D'Haese D, Ispas G, Houspie L, Van Ranst M, Stuyver LJ.

Virol J. 2014 Dec 24;11:233. doi: 10.1186/s12985-014-0233-9.

5.

Comparison of the FilmArray RP, Verigene RV+, and Prodesse ProFLU+/FAST+ multiplex platforms for detection of influenza viruses in clinical samples from the 2011-2012 influenza season in Belgium.

Van Wesenbeeck L, Meeuws H, Van Immerseel A, Ispas G, Schmidt K, Houspie L, Van Ranst M, Stuyver L.

J Clin Microbiol. 2013 Sep;51(9):2977-85. doi: 10.1128/JCM.00911-13. Epub 2013 Jul 3.

6.

HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.

Van den Eede P, Van Wesenbeeck L, Verlinden Y, Feyaerts M, Smits V, Verheyen A, Vanhooren L, Deloof A, Villacian J, Pattery T.

Methods Mol Biol. 2013;1030:37-55. doi: 10.1007/978-1-62703-484-5_5.

PMID:
23821259
7.

Evaluation of a proximity extension assay for the detection of H1 2009 pandemic influenza viruses.

Van Wesenbeeck L, Meeuws H, De Wolf H, Stuyver L.

J Virol Methods. 2013 Oct;193(1):77-84. doi: 10.1016/j.jviromet.2013.05.008. Epub 2013 May 23.

PMID:
23707923
8.

Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.

Van der Borght K, Verheyen A, Feyaerts M, Van Wesenbeeck L, Verlinden Y, Van Craenenbroeck E, van Vlijmen H.

Virol J. 2013 Jan 3;10:8. doi: 10.1186/1743-422X-10-8.

9.

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F.

J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11.

10.

The neurology of carbonic anhydrase type II deficiency syndrome.

Bosley TM, Salih MA, Alorainy IA, Islam MZ, Oystreck DT, Suliman OS, al Malki S, Suhaibani AH, Khiari H, Beckers S, van Wesenbeeck L, Perdu B, AlDrees A, Elmalik SA, Van Hul W, Abu-Amero KK.

Brain. 2011 Dec;134(Pt 12):3502-15. doi: 10.1093/brain/awr302. Epub 2011 Nov 26.

PMID:
22120147
11.

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF.

Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.

PMID:
21669228
12.

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.

Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):321-5. doi: 10.1128/AAC.01733-09. Epub 2010 Oct 18.

13.

Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone.

Chung PY, Beyens G, Riches PL, Van Wesenbeeck L, de Freitas F, Jennes K, Daroszewska A, Fransen E, Boonen S, Geusens P, Vanhoenacker F, Verbruggen L, Van Offel J, Goemaere S, Zmierczak HG, Westhovens R, Karperien M, Papapoulos S, Ralston SH, Devogelaer JP, Van Hul W.

J Bone Miner Res. 2010 Dec;25(12):2592-605. doi: 10.1002/jbmr.162. Epub 2010 Jun 18. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

14.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.

Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17.

15.

A new familial sclerosing bone dysplasia.

Chouery E, Pangrazio A, Frattini A, Villa A, Van Wesenbeeck L, Piters E, Van Hul W, Coxon FP, Schouten T, Helfrich M, Lefranc G, Mégarbané A.

J Bone Miner Res. 2010 Mar;25(3):676-80. doi: 10.1359/jbmr.090733.

16.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.

PMID:
20388636
17.

Refined genomic localization of the genetic lesion in the osteopetrosis (op) rat and exclusion of three positional and functional candidate genes, Clcn7, Atp6v0c, and Slc9a3r2.

Perdu B, Odgren PR, Van Wesenbeeck L, Jennes K, Mackay CC, Van Hul W.

Calcif Tissue Int. 2009 May;84(5):355-60. doi: 10.1007/s00223-009-9229-7. Epub 2009 Mar 4.

18.

Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's Disease of Bone.

Chung PY, Beyens G, Guañabens N, Boonen S, Papapoulos S, Karperien M, Eekhoff M, Van Wesenbeeck L, Jennes K, Geusens P, Offeciers E, Van Offel J, Westhovens R, Zmierczak H, Devogelaer JP, Van Hul W.

Calcif Tissue Int. 2008 Jul;83(1):34-42. doi: 10.1007/s00223-008-9137-2. Epub 2008 Jun 10.

PMID:
18543015
19.

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W.

Calcif Tissue Int. 2008 Jun;82(6):445-53. doi: 10.1007/s00223-008-9130-9.

PMID:
18521528
20.

A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts.

Del Fattore A, Fornari R, Van Wesenbeeck L, de Freitas F, Timmermans JP, Peruzzi B, Cappariello A, Rucci N, Spera G, Helfrich MH, Van Hul W, Migliaccio S, Teti A.

J Bone Miner Res. 2008 Mar;23(3):380-91.

Supplemental Content

Loading ...
Support Center